NASDAQ:ATHX

Athersys (ATHX) Stock Forecast, Price & News

$0.43

+0.07 (+19.33%)

(As of 09/29/2023 ET)

Compare

Today's Range: $0.38
▼
$0.45
50-Day Range: $0.28
▼
$0.80
52-Week Range: $0.26
▼
$2.76

Volume: 839,180 shs
Average Volume: 274,411 shs
Market Capitalization: $9.72 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.50

Athersys MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,172.9% Upside
$5.50 Price Target
Short Interest: Healthy
3.62% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.34
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Athersys has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.50, Athersys has a forecasted upside of 1,172.9% from its current price of $0.43.
Amount of Analyst Coverage
Athersys has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
3.62% of the float of Athersys has been sold short.
Short Interest Ratio / Days to Cover
Athersys has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Athersys has recently decreased by 0.25%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Athersys does not currently pay a dividend.
Dividend Growth
Athersys does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ATHX.

2.4

News and Social Media Coverage

News Sentiment
Athersys has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Athersys this week, compared to 0 articles on an average week.
Search Interest
Only 4 people have searched for ATHX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
2 people have added Athersys to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Athersys insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.03% of the stock of Athersys is held by insiders.
Percentage Held by Institutions
Only 19.35% of the stock of Athersys is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Athersys is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Athersys is -0.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Athersys (NASDAQ:ATHX) Stock

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. The company was founded in 1995 and is headquartered in Cleveland, Ohio.

ATHX Price History

30 days | 90 days | 365 days | Advanced Chart

ATHX Stock News Headlines

September 26, 2023 | finance.yahoo.com

Athersys Slumps as MultiStem Fails in Mid-Stage Study - Analyst Blog

September 25, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on Athersys (NASDAQ:ATHX)

September 29, 2023 | Tradewins (Ad)

Successful Options Trading Begins With…

Options trading expert Wendy Kirkland’s free guide reveals the options trading principles that are as easy to implement as they are to learn and how using them could earn you thousands in extra income each month!

September 6, 2023 | finance.yahoo.com

Grant Awarded to Newcastle University to Research Athersys’ MultiStem® in Machine Perfusion Prior to Kidney Transplantation

August 25, 2023 | finance.yahoo.com

Is Athersys Inc (ATHX) Significantly Overvalued?

August 18, 2023 | marketwatch.com

Athersys Shares Tumble 26% After Pricing Public Offering

August 18, 2023 | investorplace.com

Why Is Athersys (ATHX) Stock Down 36% Today?

August 18, 2023 | seekingalpha.com

Athersys shares slide on pricing $3.5 million stock offering

September 29, 2023 | Tradewins (Ad)

Successful Options Trading Begins With…

August 18, 2023 | finance.yahoo.com

Athersys, Inc. Announces Pricing of $3.5 Million Public Offering

August 16, 2023 | finance.yahoo.com

Athersys Reports Second Quarter 2023 Financial Results and Business Highlights

August 11, 2023 | finance.yahoo.com

Athersys Appoints Neema Mayhugh, PhD to its Board of Directors

August 11, 2023 | bizjournals.com

Athersys executives foresee catalysts that could ease its financial journey

July 31, 2023 | businesswire.com

Athersys to Host Business Update Conference Call on August 9th

July 30, 2023 | fool.com

Athersys (NASDAQ: ATHX)

June 1, 2023 | tmcnet.com

Patient Enrollment Begins in Third and Final Cohort

June 1, 2023 | finance.yahoo.com

Patient Enrollment Begins in Third and Final Cohort of the Phase 2 MATRICS-1 Clinical Study Evaluating Athersys’ MultiStem® Following Hemorrhagic Trauma

May 23, 2023 | msn.com

Athersys restructures debt with supplier, prioritizing multi-stem for stroke treatment

May 23, 2023 | finance.yahoo.com

Athersys Restructures Debt with Supplier

May 18, 2023 | bizjournals.com

Athersys cuts quarterly loss as restructuring takes hold

May 18, 2023 | finance.yahoo.com

Athersys Reports First Quarter 2023 Financial Results and Business Highlights

May 8, 2023 | finance.yahoo.com

Athersys to Participate in Three Upcoming Conferences

May 1, 2023 | finance.yahoo.com

Athersys to Participate in The Cellular Therapies and Transfusion Medicine in Trauma and Critical Care Conference

April 21, 2023 | finance.yahoo.com

Athersys to Participate in The American Society for Neural Therapy and Repair Annual Conference

April 19, 2023 | finance.yahoo.com

Athersys, Inc. Announces Closing of $3.7 Million Registered Direct Offering and Concurrent Private Placement

April 18, 2023 | finance.yahoo.com

Athersys, Inc. Announces $3.7 Million Registered Direct Offering and Concurrent Private Placement

April 12, 2023 | businesswire.com

Athersys to Host Business Update Conference Call on April 20 th

See More Headlines

Receive ATHX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter.

ATHX Company Calendar

Last Earnings: 8/16/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/13/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ATHX
CUSIP: N/A
CIK: 1368148
Web: www.athersys.com
Phone: (216) 431-9900
Fax: 216-361-9495
Employees: 24
Year Founded: 1995

Price Target and Rating

Average Stock Price Forecast: $5.50
High Stock Price Forecast: $5.50
Low Stock Price Forecast: $5.50
Forecasted Upside/Downside: +1,207.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.03)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-72,530,000.00
Net Margins: -1,362.14%
Pretax Margin: -32,469.17%
Return on Equity: N/A
Return on Assets: -198.80%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.09
Quick Ratio: 0.09

Sales & Book Value

Annual Sales: $5.32 million
Price / Sales: 1.78
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.33) per share
Price / Book: -0.32

Miscellaneous

Outstanding Shares: 22,500,000
Free Float: 22,494,000
Market Cap: $9.46 million
Optionable: Optionable
Beta: -0.74

Social Links

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Daniel A. Camardo M.B.A. (Age 54)
CEO, Sec., Principal Accounting Officer & Director
Comp: $796.81k

Ms. Z. Kasey Rosado (Age 49)
Interim Chief Financial Officer
Comp: $1.51M

Ms. Maia A. Hansen M.B.A. (Age 54)
M.S., Chief Operating Officer
Comp: $962.57k

Senthil Ranganathan Ph.D.
VP of Technical Operations

Mr. David Russ M.B.A.
VP of Supply Chain, Fin. & Admin.

Dr. Manal Morsy M.B.A.
M.D., PH.D., Exec. VP & Head of Global Regulatory Affairs

Dr. Robert Mays Ph.D.
Exec. VP, Head of Regenerative Medicine & Neuroscience Programs

Mr. Rakesh Ramachandran MS
Head of Information Technology & Communications and VP

Dr. Sarah Busch Ph.D.
VP of Regenerative Medicine & Head of Bus. Devel.

Ms. Ellen Gurley
Mang. of Corp. Communications and Investor Relations

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

ATHX Stock - Frequently Asked Questions

Should I buy or sell Athersys stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATHX shares.
View ATHX analyst ratings or view top-rated stocks.
What is Athersys' stock price forecast for 2023?: 1 analysts have issued 12-month target prices for Athersys' stock. Their ATHX share price forecasts range from $5.50 to $5.50. On average, they expect the company's stock price to reach $5.50 in the next twelve months. This suggests a possible upside of 1,207.7% from the stock's current price.
View analysts price targets for ATHX or view top-rated stocks among Wall Street analysts.
How have ATHX shares performed in 2023?: Athersys' stock was trading at $0.84 at the start of the year. Since then, ATHX shares have decreased by 49.9% and is now trading at $0.4206.
View the best growth stocks for 2023 here.
When is Athersys' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ATHX earnings forecast.
How were Athersys' earnings last quarter?: Athersys, Inc. (NASDAQ:ATHX) announced its earnings results on Wednesday, August, 16th. The biopharmaceutical company reported ($0.62) EPS for the quarter. The biopharmaceutical company earned $0.05 million during the quarter.
When did Athersys' stock split?: Shares of Athersys reverse split on the morning of Monday, August 29th 2022. The 1-25 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What is William (B.J.) Lehmann's approval rating as Athersys' CEO?: 1 employees have rated Athersys Chief Executive Officer William (B.J.) Lehmann on Glassdoor.com. William (B.J.) Lehmann has an approval rating of 100% among the company's employees. This puts William (B.J.) Lehmann in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 65.0% of employees surveyed would recommend working at Athersys to a friend.
What other stocks do shareholders of Athersys own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Athersys investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Vaxart (VXRT), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), T2 Biosystems (TTOO) and ADMA Biologics (ADMA).
What is Athersys' stock symbol?: Athersys trades on the NASDAQ under the ticker symbol "ATHX."
How do I buy shares of Athersys?: Shares of ATHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Athersys' stock price today?: One share of ATHX stock can currently be purchased for approximately $0.42.
How much money does Athersys make?: Athersys (NASDAQ:ATHX) has a market capitalization of $9.46 million and generates $5.32 million in revenue each year. The biopharmaceutical company earns $-72,530,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis.
How can I contact Athersys?: Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The official website for the company is www.athersys.com. The biopharmaceutical company can be reached via phone at (216) 431-9900, via email at ir@athersys.com, or via fax at 216-361-9495.

This page (NASDAQ:ATHX) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial